24/7 Market News Snapshot 13 August, 2025 – Longeveron Inc. Common Stock (NASDAQ:LGVN)

August 13, 2025

DENVER, Colo., 13 August, 2025 (www.247marketnews.com) – (NASDAQ:LGVN) are discussed in this article.
Longeveron Inc. (NASDAQ:LGVN) is making significant strides in the biotechnology sector, recently garnering considerable attention from investors. The stock opened at $0.696 and experienced a remarkable surge to $0.821, reflecting an increase of over 20.65%. This momentum was supported by a robust trading volume of 19.05 million shares, indicating strong investor enthusiasm for the company’s pioneering work in regenerative medicine.

In a noteworthy development, Longeveron announced the full enrollment of 40 pediatric patients in its pivotal Phase 2b clinical trial, ELPIS II, which investigates laromestrocel, an innovative allogeneic stem cell therapy, for treating Hypoplastic Left Heart Syndrome (HLHS). This serious congenital heart defect poses significant risks for affected children, and the trial, conducted in collaboration with the National Heart, Lung, and Blood Institute, aims to assess the therapy’s efficacy as an adjunct treatment. Preliminary results from this trial are projected for release in the third quarter of 2026, following a comprehensive 12-month patient follow-up period.

Wa’el Hashad, the Chief Executive Officer of Longeveron, emphasized the importance of this accomplishment in advancing cellular therapies, highlighting the potential of laromestrocel to improve clinical outcomes for those diagnosed with HLHS. The company is also preparing for a potential Biological License Application (BLA) submission by late 2026, contingent on positive trial results.

Beyond its focus on HLHS, Longeveron recently received FDA approval for an Investigational New Drug (IND) application to explore laromestrocel as a treatment for Pediatric Dilated Cardiomyopathy (DCM), with a pivotal Phase 2 trial set to commence in early 2026. Through these initiatives, Longeveron demonstrates its commitment to addressing critical unmet medical needs across various age groups, particularly in pediatric and aging populations, while also pursuing strategic partnerships to further bolster its regenerative medicine pipeline.

Related news for (LGVN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.